{"abstract": "Amgen\u2019s deal to buy Onyx Pharmaceuticals shows the value of having a tough negotiator at the helm, the author writes.", "web_url": "https://dealbook.nytimes.com/2013/09/05/amgen-investors-gain-from-having-an-ex-investment-banker-as-c-e-o/", "snippet": "Amgen\u2019s deal to buy Onyx Pharmaceuticals shows the value of having a tough negotiator at the helm, the author writes.", "lead_paragraph": "An investment banker as chief executive may have some merits \u2013 at least Amgen shareholders should think so. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Investors Gain From Having an Ex-Investment Banker as C.E.O.", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "persons", "value": "Bradway, Robert A", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Onyx Pharmaceuticals", "rank": 5, "major": "N"}], "pub_date": "2013-09-05T16:28:25+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Rob Cox", "person": [{"firstname": "Rob", "middlename": null, "lastname": "Cox", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d44e1b48-a6f6-5381-ae25-654d1e7a23ed", "word_count": 412, "uri": "nyt://article/d44e1b48-a6f6-5381-ae25-654d1e7a23ed"}